Collaboration aims to enhance cardiac monitoring, early diagnosis, and remote patient care through next-generation AI-ECG innovation
New York, March 16, 2026 – HeartBeam, Inc., a medical technology company focused on advancing cardiac diagnostics, has announced a strategic collaboration with the Icahn School of Medicine at Mount Sinai in New York. The partnership is aimed at accelerating the development and validation of next-generation artificial intelligence-based electrocardiogram (AI-ECG) algorithms designed to improve how heart conditions are detected and monitored.
The collaboration will combine HeartBeam’s patented ECG technology with Mount Sinai’s extensive clinical datasets and expertise in artificial intelligence. Together, the two organizations aim to develop more advanced AI models that can support physicians in identifying heart conditions earlier and managing patient care more effectively.
HeartBeam’s technology captures the heart’s electrical activity from three non-coplanar directions, allowing it to create a three-dimensional view of cardiac signals. These signals can then be synthesized into a standard 12-lead ECG, which is widely used in clinical settings to diagnose heart diseases. Unlike traditional ECG systems that require multiple wires and hospital equipment, HeartBeam’s system is designed to be cable-free and portable, allowing patients to monitor their heart activity from home.
As part of the collaboration, Mount Sinai will provide clinically annotated 12-lead ECG datasets and contribute its research expertise in artificial intelligence and clinical analysis. These datasets will be combined with high-fidelity ECG data generated by HeartBeam’s platform, including signals collected from patients in home environments.
By using both clinical and real-world data, researchers aim to accelerate the training and validation of AI algorithms capable of identifying cardiac patterns, risk indicators, and potential abnormalities. The technology could support more personalized cardiac insights and improve the ability of healthcare providers to monitor patients remotely.
The partnership also aims to expand the potential clinical applications of AI-ECG technology. Researchers believe that combining advanced algorithms with large datasets may help develop tools for preventive cardiology, chronic disease management, and continuous remote patient monitoring.
HeartBeam has already achieved important regulatory progress for its technology. In December 2024, the company received clearance from the U.S. Food and Drug Administration for its 3D ECG technology used in arrhythmia assessment. This was followed by FDA clearance in December 2025 for its software capable of synthesizing a 12-lead ECG from the device’s three-directional signal recordings.
The company currently holds more than 20 issued patents supporting its ECG platform technology. With the growing adoption of digital health solutions, the collaboration between HeartBeam and Mount Sinai highlights how artificial intelligence, medical technology innovation, and advanced cardiac monitoring tools are shaping the future of cardiovascular care.